Flagship Pioneering Inc.

13F Filings History

Latest 13F report
Q4 2024 - Feb 14, 2025
Value $
$334M
Notable people
Noubar B. Afeyan
Signature - Title
Noubar B. Afeyan, Ph.D. - Chief Executive Officer
Location
Cambridge, MA
Summary
This page shows a list of all the recent 13F filings made by Flagship Pioneering Inc.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Flagship Pioneering Inc. reported 5 stock holdings with total value $334M as of Q4 2024. Top holdings included MRNA, FHTX, SANA, OMGA, and MCRB.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q4 2024 5 $334M $0 -$2.78M -$2.78M MRNA, FHTX, SANA, OMGA, MCRB 13F-HR 2/14/2025, 04:00 PM
Q3 2024 6 $592M $0 $0 MRNA, FHTX, SANA, OMGA, MCRB 13F-HR 11/14/2024, 04:00 PM
Q2 2024 6 $843M $0 -$626M -$626M MRNA, SANA, FHTX, OMGA, MCRB 13F-HR 8/14/2024, 04:00 PM
Q1 2024 6 $1.27B +$5.00 -$19.6M -$19.6M MRNA, OMGA, FHTX, DNLI, MCRB 13F-HR 5/15/2024, 04:00 PM
Q4 2023 7 $1.33B +$2.34M -$49.7M -$47.4M MRNA, SANA, OMGA, FHTX, DNLI 13F-HR 2/14/2024, 04:00 PM
Q3 2023 11 $1.38B +$33.4M -$389M -$356M MRNA, SANA, FHTX, OMGA, MCRB 13F-HR 11/14/2023, 04:00 PM
Q2 2023 13 $2.24B +$26.2M -$25M +$1.12M MRNA, SANA, OMGA, MCRB, FHTX 13F-HR 8/14/2023, 05:00 PM
Q1 2023 11 $2.57B +$20M +$20M MRNA, OMGA, MCRB, SANA, FHTX 13F-HR 5/15/2023, 04:00 PM
Q4 2022 11 $2.84B +$3.32M +$3.32M MRNA, SANA, MCRB, EVLO, FHTX 13F-HR 2/14/2023, 12:00 PM
Q3 2022 12 $2.38B +$63.2M +$63.2M MRNA, SANA, MCRB, OMGA, FHTX 13F-HR 11/14/2022, 03:00 PM
Q2 2022 12 $2.65B +$57.8M -$671M -$613M MRNA, SANA, FHTX, EVLO, OMGA 13F-HR 8/15/2022, 04:02 PM
Q1 2022 13 $4.26B +$16.2M +$16.2M MRNA, SANA, RUBY, FHTX, OMGA 13F-HR 5/16/2022, 03:01 PM
Q4 2021 13 $6.47B -$4.92M -$4.92M MRNA, SANA, RUBY, OMGA, FHTX 13F-HR 2/14/2022, 02:01 PM
Q3 2021 13 $9.55B +$488M $0 +$488M MRNA, SANA, RUBY, OMGA, FHTX 13F-HR 11/15/2021, 04:01 PM
Q2 2021 0 $0 $0 $0 13F-HR 8/16/2021, 08:59 AM
Q1 2021 0 $0 $0 $0 13F-HR 5/17/2021, 04:30 PM
Q4 2020 0 13F-HR 2/16/2021, 04:10 PM
Q3 2020 8 $3.62B -$708M -$708M MRNA, MCRB, KLDO, DNLI, RUBY 13F-HR 11/16/2020, 03:00 PM
Q2 2020 8 $3.44B +$58.7M -$706M -$648M MRNA, RUBY, DNLI, KLDO, EVLO 13F-HR 8/13/2020, 04:01 PM
Q1 2020 8 $2.13B MRNA, RUBY, DNLI, KLDO, MCRB 13F-HR 5/14/2020, 04:16 PM
Q4 2019 8 $1.79B MRNA, RUBY, DNLI, KLDO, MCRB 13F-HR 2/13/2020, 03:17 PM
Q3 2019 7 $591M KLDO, DNLI, EVLO, MCRB, TMDX 13F-HR 11/14/2019, 03:15 PM
Q2 2019 10 $2.31B +$183M -$6.93M +$176M MRNA, RUBY, KLDO, DNLI, EVLO 13F-HR 8/13/2019, 04:15 PM
Q1 2019 8 $2.64B +$252M -$21.2M +$231M MRNA, RUBY, KLDO, DNLI, EVLO 13F-HR 5/14/2019, 04:10 PM
Q4 2018 7 $2.05B +$898M +$898M MRNA, RUBY, EVLO, DNLI, MCRB 13F-HR 2/12/2019, 05:44 PM
Q3 2018 6 $1.51B +$919M +$919M RUBY, EVLO, DNLI, MCRB, QTRX 13F-HR 11/13/2018, 09:14 AM
Q2 2018 5 $522M +$215M +$215M EVLO, DNLI, MCRB, SYRS, QTRX 13F-HR 8/7/2018, 04:26 PM
Q1 2018 4 $345M DNLI, MCRB, SYRS, QTRX 13F-HR 5/15/2018, 04:05 PM
Q4 2017 5 $394M DNLI, MCRB, EDIT, QTRX, SYRS 13F-HR 2/13/2018, 05:34 PM
Q3 2017 0 13F-HR 11/3/2017, 10:23 AM
Q2 2017 4 $284M MCRB, SYRS, EDIT, TTOO 13F-HR 8/2/2017, 03:46 PM
Q1 2017 7 $376M -$1.77M -$1.77M MCRB, SYRS, EDIT, AGIO, SELB 13F-HR 5/10/2017, 04:28 PM
Q4 2016 7 $307M -$17.3M -$17.3M MCRB, SYRS, EDIT, AGIO, SELB 13F-HR 2/13/2017, 01:28 PM
Q3 2016 7 $366M MCRB, SYRS, AGIO, EDIT, SELB 13F-HR 11/14/2016, 08:53 AM